Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

What to Expect From Eli Lilly’s Q4 2025 Earnings Report

Eli Lilly is gearing up to announce its fiscal 2025 fourth-quarter earnings in the near term, and analysts project its earnings to rise in double-digits.

Barchart

New fleet of weight loss drugs are more effective than the current popular obesity medications at trial

One in eight Americans are taking a GLP-1 drug, a recent poll found

The Independent UK

This NVIDIA Partnership Shows How Big AI Can Really Get

NVIDIA is well-positioned to dominate AI markets across industries and verticals for years to come; analysts point to a 40% upside.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Amazon starts to offer Wegovy weight loss pill to customers

The new oral Wegovy, launched this week, contains semaglutide, the same active ingredient as injectable Wegovy and Ozempic

The Independent UK

Flu Season's Here—This Dividend-Payer Controls the Shot Market

With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket.

MarketBeat

Novo Nordisk launches Wegovy weight-loss pill in US, triggering price war

First and only GLP-1 pill on the market costs significantly less than injectable versions

The Guardian - UK

Novo Nordisk's Future Vision on 'Weight Loss' Wins Scientists, Tests Wall Street's Patience

Novo Nordisk's long-term strategy for weight-loss treatments has earned praise from scientists, even as investors grow cautious about timelines, competition and near-term returns.

International Business Times UK

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026

Eli Lilly has been a huge winner in the last few months of 2025. New clinical data support its outlook in 2026, with large potential catalysts on the horizon.

MarketBeat

As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?

As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now?

Barchart

Asian shares are mixed after US stocks drift to more records

Asian shares are mixed in thin holiday trading, with most markets in the region and elsewhere closed for Christmas

The Independent UK

India’s doctors sound alarm over boom in availability of weight loss jabs

Country is facing epidemic of diabetes and obesity, but experts say widespread and unregulated use of weight loss drugs could put patients at risk

The Guardian - UK

More drug companies sign on to Trump’s health exchange that promises to lower prescription prices

Administration officials say the ‘Trump Rx’ website should be up and running next month

The Independent UK

Pfizer Adds to Its Big Bet on Weight Loss Drugs

A month after acquiring obesity biotech Metsera, Pfizer's expanding in the weight loss drug market after signing a licensing agreement for a weight loss pill.

MarketBeat

A better Ozempic? Eli Lilly’s new obesity drug cut weight by 23%, study finds

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic knee pain after 68 weeks

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

International Business Times UK

Eli Lilly CEO David Ricks Unveils $6B Alabama Plant to Produce New Obesity Pill

Eli Lilly CEO David Ricks has announced a new $6 billion manufacturing plant in Alabama dedicated to producing the company's next-generation obesity pill. The move signals Lilly's aggressive expansion as global demand for weight-loss drugs soars.

Benzinga

Healthcare Relevancies Clashes With Premium Valuations For Direxion's LLY-Focused ELIL, ELIS ETFs

In terms of sheer relevance, it's difficult to think of a more relevant sector than healthcare — and within this vast ecosystem, only an elite few occupy the same neighborhood as pharmaceutical giant Eli Lilly and Company (NYSE:LLY). In November 2025, Eli Lilly became the first trillion-dollar pharmaceutical company, mostly…

International Business Times

Eli Lilly, Pfizer Among 19 Drugs Approved for China's Commercial Health Insurance

China approves 19 innovative drugs for commercial health insurance, opening new market opportunities for global and local drugmakers.

Benzinga

What's Up With The Jump In Viking Therapeutics Stock?

Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher on Thursday. The clinical-stage biopharmaceutical company seems to be benefitting from wider excitement in the obesity treatment area, as well as recent positive momentum after major clinical trial developments.

Get all your
news in one place.

100’s of premium titles.
One news app.

International Business Times UK

Zepbound 30% Price Cut to $299 Still Far Above Cheaper Overseas Options

Eli Lilly slashes Zepbound to £227 ($299) monthly for US cash payers, but just £31 ($41) in India – though £241 ($319) in Japan.

MarketBeat

5 Healthcare Names to Watch as Sector Rotation Is in Full Swing

The healthcare sector is outperforming the broader market and tech sector in Q4, confirming a substantial capital shift into the defensive industry.

Axios

Weight loss drugs go from niche to mainstream

New pricing deals and aggressive marketing are transforming GLP-1s.

Benzinga

A Conductor For The Orchestra: Seasoned Healthcare Executive Raises $52 Million For An AI Health Startup

Michelle Carnahan has spent the better part of the last three decades working in healthcare at companies like Thirty Madison and Eli Lilly (NYSE:LLY). Now, the entrepreneur has raised $52 million in seed money for her own startup, Arbiter, a platform that connects health care professionals and payers to provide…

Barchart

Eli Lilly’s Stock Price Has Fattened Up Like a Thanksgiving Turkey. Time to (Options) Collar That Green!

As Eli Lilly makes history by joining the $1 trillion club, here’s how you can position for its next move.

Benzinga

The AI Pharma Rally Is Real — And Cancer May Soon Be Chronic, Not Deadly

Pharma stocks have recently emerged as one of Wall Street's hottest trades, with November marking a striking inflection point few had expected.

Benzinga

Healthcare ETFs Trounce Tech, Grab Billions As Big Money Flees Bubble Fears

A powerful rotation into healthcare is taking shape across global markets, with investors pouring money into sector ETFs at one of the fastest clips this year. What started as a cautious move toward defensive stability has quickly morphed into a broader enthusiasm for biotech, pharma and healthcare-services names – helped…

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.